Université de Liège (ULg), Centre d'Ingénierie des Protéines (CIP), Bâtiment B6, Allée du 6 Août, Sart-Tilman, B-4000 Liège, Belgium.
Eur J Med Chem. 2013 Jun;64:365-76. doi: 10.1016/j.ejmech.2013.03.052. Epub 2013 Apr 15.
Assuming that bicyclic β-lactams endowed with high conformational adaptability should more easily form acyl-enzyme complexes with PBP2a than the traditional antibiotics, we have prepared a series of bis-2-oxo-azetidinyl macrocycles as potential inhibitors. The compounds are formally "head-head" (HH) cyclodimers of 1-(ω-alkenoyl)-3-(S)-(ω'-alkenoylamino)-2-azetidinones, with various lengths of the alkene chains, obtained by two successive metathesis reactions using the Grubbs catalyst. All compounds behave as acylating inhibitors of PBP2a and one β-lactam (5c), embedded into the largest ring (32 atoms), features an activity close to that of Ceftobiprole. Conformational analyses, theoretical reactivity models and docking experiments in PBP2a cavity allow to propose a novel pharmacophore, i.e. the 3-(S)-acylamino-1-acyl-2-azetidinone ring, with the syn-conformation of the imide function, associated to a flexible macrocycle favoring the opening of the active site.
假设具有高构象适应性的双环β-内酰胺应该比传统抗生素更容易与 PBP2a 形成酰基-酶复合物,我们已经制备了一系列双-2-氧代-氮杂环丁烷作为潜在的抑制剂。这些化合物是通过使用 Grubbs 催化剂的两次复分解反应获得的 1-(ω-烯酰基)-3-(S)-(ω'-烯酰胺基)-2-氮杂环丁酮的正式“头对头”(HH)环二聚体,具有不同长度的烯链。所有化合物均表现为 PBP2a 的酰化抑制剂,其中一个β-内酰胺(5c),嵌入最大环(32 个原子)中,其活性接近头孢妥洛普。构象分析、理论反应性模型和在 PBP2a 腔中的对接实验允许提出一个新的药效团,即 3-(S)-酰氨基-1-酰基-2-氮杂环丁酮环,具有酰胺功能的顺式构象,与有利于活性位点打开的柔性大环相关联。